- Home
- SLXN vs SSY Comparison
SLXN vs SSY Comparison
Compare SLXN & SSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- SSY
- Stock Information
- Founded
- SLXN 2008
- SSY 1959
- Country
- SLXN Israel
- SSY United States
- Employees
- SLXN N/A
- SSY N/A
- Industry
- SLXN
- SSY Hospital/Nursing Management
- Sector
- SLXN
- SSY Health Care
- Exchange
- SLXN NYSE
- SSY Nasdaq
- Market Cap
- SLXN 7.3M
- SSY 6.2M
- IPO Year
- SLXN N/A
- SSY N/A
- Fundamental
- Price
- SLXN $0.83
- SSY $1.13
- Analyst Decision
- SLXN Strong Buy
- SSY
- Analyst Count
- SLXN 1
- SSY 0
- Target Price
- SLXN $5.00
- SSY N/A
- AVG Volume (30 Days)
- SLXN 784.5K
- SSY 104.5K
- Earning Date
- SLXN 08-21-2025
- SSY 05-13-2025
- Dividend Yield
- SLXN N/A
- SSY N/A
- EPS Growth
- SLXN N/A
- SSY N/A
- EPS
- SLXN N/A
- SSY 0.25
- Revenue
- SLXN N/A
- SSY $31,094,000.00
- Revenue This Year
- SLXN N/A
- SSY N/A
- Revenue Next Year
- SLXN N/A
- SSY N/A
- P/E Ratio
- SLXN N/A
- SSY $4.57
- Revenue Growth
- SLXN N/A
- SSY N/A
- 52 Week Low
- SLXN $0.58
- SSY $0.62
- 52 Week High
- SLXN $41.85
- SSY $1.91
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- SSY 70.32
- Support Level
- SLXN N/A
- SSY $0.87
- Resistance Level
- SLXN N/A
- SSY $1.25
- Average True Range (ATR)
- SLXN 0.00
- SSY 0.08
- MACD
- SLXN 0.00
- SSY 0.02
- Stochastic Oscillator
- SLXN 0.00
- SSY 68.42
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About SSY SunLink Health Systems Inc.
SunLink Health Systems Inc is engaged in providing retail pharmacy services. The company operates its business through segments namely the Healthcare Services segment and Pharmacy segment. The Healthcare Services segment includes subsidiaries that own and operate licensed-bed, acute care hospitals, which includes bed geriatric psychology unit, and nursing home; own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land; and provides information technology to outside customers. The Pharmacy segment, which is the key revenue generator is composed of retail pharmacy products and services that are conducted in rural markets; institutional pharmacy services; pharmacy services; and durable medical equipment.